SMTL ID : 9f2h.1 (1 other biounit)

Crystal structure of SARS-CoV-2 N-protein C-terminal domain in complex with riluzole

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 1.30 Å

Oligo State

homo-dimer

Ligands

1 x 657: 6-(trifluoromethoxy)-1,3-benzothiazol-2-amine(Non-covalent)

657.1: 7 residues within 4Å: Chain A: Q.28, T.29, E.70, T.72, W.77, T.79 Chain B: A.83 4 PLIP interactions: 4 interactions with chain A Hydrophobic interactions: A:E.70, A:T.79 Water bridges: A:E.70, A:T.79

2 x SO4: SULFATE ION(Non-functional Binders)

SO4.2: 1 residues within 4Å: Chain A: R.9 2 PLIP interactions: 2 interactions with chain A Water bridges: A:R.9 Salt bridges: A:R.9 SO4.3: 2 residues within 4Å: Chain B: S.2, R.9 3 PLIP interactions: 3 interactions with chain B Hydrogen bonds: B:S.2, B:S.2 Salt bridges: B:R.9

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Marquez-Monino, M.A. et al., The ALS drug riluzole binds to the C-terminal domain of SARS-CoV-2 nucleocapsid protein and has antiviral activity. Structure (2024)

Release Date

2024-11-13

Peptides

Nucleoprotein: AB

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
B

Nucleoprotein

Related Entries With Identical Sequence